Krishna Ella — MDRPedia
Krishna Ella
Top 1% — Elite

Krishna Ella

Vaccinology - Covaxin development

India

110 H-Index
1,153 Total Impact

Overview

Krishna Ella is a vaccinology - covaxin development specialist with an H-index of 110 at Bharat Biotech (Faculty). Has been published in The Lancet Infectious Diseases, The Lancet, iScience. Based in India.

Biography

Krishna Ella is an Indian scientist and entrepreneur. He is the co-founder and Executive Chairman of Bharat Biotech, a biotechnology company known for developing Covaxin, India's first indigenous COVID-19 vaccine, in collaboration with the Indian Council of Medical Research (ICMR). Bharat Biotech was also involved in the development of ROTAVAC, a vaccine against rotavirus, in collaboration with Department of Biotechnology (DBT), Government of India, and international partners, including the Rotavirus Vaccine Development Program (RVDP) of PATH and the National Institutes of Health (NIH), USA; and Typbar TCV, a typhoid conjugate vaccine. Ella worked as a research faculty member at the Medical University of South Carolina in Charleston after earning his Ph.D. from the University of Wisconsin–Madison. In 2022, Ella and his wife, Suchitra Ella, received the Padma Bhushan, India's third-highest civilian award, for their contributions to trade and industry.

Affiliations & Institutions

Research Impact

5 Publications
0 Total Citations

Publication Timeline

01120082017202020242025

Published In

Nat MedCellsJ Chromatogr B Analyt Technol Biomed Life SciIndian PediatrSci Rep

Key Publications

Renaturation, purification and characterization of streptokinase expressed as inclusion body in recombinant E. coli.
J Chromatogr B Analyt Technol Biomed Life Sci 2008
Coronavirus Vaccine: Light at the End of the Tunnel.
Indian Pediatr 2020

Areas of Expertise

Medical Specialties

Clinical Knowledge & Procedures

Media Archive

Portrait of Krishna Ella
Feature Portrait